Add to Calendar 8/26/2020 8:00:00 AM 8/27/2020 5:00:00 PM 2020 State of Possible Conference

Special thanks to our Platinum Sponsor Morgan Stanley

Registered attendees will receive an email with the subject line “Welcome to the State of Possible Conference 2020 - Event Access Link” from registrations@bizzabo.com.


The State of Possible Conference, MassBio's Annual Meeting, will now be hosted virtually on August 26-27, 2020. Featuring interactive networking and a groundbreaking viewer experience, this event will not be your average webinar.  

We will celebrate what’s possible in our industry and for patients today that wasn’t five or 10 years ago. The two-day event will draw over 600 industry leaders from Massachusetts and beyond to debate the most pressing challenges facing the life sciences to ensure we can continue this incredible success. Attendees will hear from the brightest minds through keynotes, panel discussions and 15-minute Possible Talks®, inspiring and engaging content in the style of a TED Talk.

"It's the Woodstock of Life Sciences, with all-star performers playing their greatest hits all on one stage.” – 2019 State of Possible Conference attendee
 
If you haven’t attended our State of Possible Conference before, it is the premier east coast life sciences conference. We have some of the brightest names in biotech talking about the issues impacting our industry, covering topics from the realities of precision medicine to advancing new drug targets faster.

To inquire about sponsorship opportunities, contact Laura Rudberg.

2020 State of Possible Conference Refund Policy

NOTE: MassBio makes every effort to accommodate our entire community at each of our events. Please let us know at least 3 days in advance of the event if you require special accommodations, such as captioning.
 Online Conference, Link will be sent in advance of the event.
Founder & CEO, PTC Therapeutics, Inc.
Dr. Stuart Peltz founded PTC Therapeutics in 1998 and has served as Chief Executive Officer and a member of the board of directors since the company’s inception. Under his leadership, PTC has grown from a research organization to a publicly traded, global commercial organization with multiple approved products and a foundation of strong technology platforms that continues to drive a robust discovery pipeline for patients with rare disorders. Prior to founding PTC, Dr. Peltz was a Professor in the Department of Molecular Genetics & Microbiology at the Robert Wood Johnson Medical School, Rutgers University. Dr. Peltz is a recognized scientific leader in RNA biology in the area of post-transcriptional control processes involving mRNA turnover and translation, with more than 30 years of research and over 100 publications in this area. Dr. Peltz has received a number of business and scientific awards. Notably, he was elected as a Fellow of the American Academy for the Advancement of Science in 2010. He was recognized as PharmaVoice’s 100 Most Inspiring People in 2009 and received the Dr. Sol J. Barer Award for Vision Innovation and Leadership in 2014. Dr. Peltz earned a Ph.D. from the McArdle Laboratory for Cancer Research at the University of Wisconsin.

Brought to you by